Abstract
Exosomes and biomimetic nanoparticles have great potential to develop into a wide-scale therapeutic platform within the regenerative medicine industry. Exosomes, a subgroup of EVs with diameter ranging from 30-100 nm, have recently gained attention as an innovative approach for the treatment of various diseases, including heart disease. Their beneficial factors and regenerative properties can be contrasted with various cell types. Various biomimetic nanoparticles have also emerged as a unique platform in regenerative medicine. Biomimetic nanoparticles are a drug delivery platform, which have the ability to contain both biological and fabricated components to improve therapeutic efficiency and targeting. The novelty of these platforms holds promise for future clinical translation upon further investigation. In order for both exosome therapeutics and biomimetic nanoparticles to translate into large-scale clinical treatment, numerous factors must first be considered and improved. Standardization of different protocols, from exosome isolation to storage conditions, must be optimized to ensure batches are pure. Standardization is also important to ensure no variability in this process across studies, thus making it easier to interpret data across different disease models and treatments. Expansion of clinical trials incorporating both biomimetic nanoparticles and exosomes will require a standardization of fabrication and isolation techniques, as well as stricter regulations to ensure reproducibility across various studies and disease models. This review will summarize current research on exosome therapeutics and the application of biomimetic nanoparticles in cardiac regenerative medicine, as well as applications for exosome expansion and delivery on a large clinical scale.
Keywords: Exosomes, regenerative medicine, biomimetic nanoparticles, drug delivery, extracellular vesicles, mesenchymal stem cells, secretome.
Current Stem Cell Research & Therapy
Title:Exosome and Biomimetic Nanoparticle Therapies for Cardiac Regenerative Medicine
Volume: 15 Issue: 8
Author(s): Sydney J. Stine, Kristen D. Popowski, Teng Su and Ke Cheng*
Affiliation:
- Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC,United States
Keywords: Exosomes, regenerative medicine, biomimetic nanoparticles, drug delivery, extracellular vesicles, mesenchymal stem cells, secretome.
Abstract: Exosomes and biomimetic nanoparticles have great potential to develop into a wide-scale therapeutic platform within the regenerative medicine industry. Exosomes, a subgroup of EVs with diameter ranging from 30-100 nm, have recently gained attention as an innovative approach for the treatment of various diseases, including heart disease. Their beneficial factors and regenerative properties can be contrasted with various cell types. Various biomimetic nanoparticles have also emerged as a unique platform in regenerative medicine. Biomimetic nanoparticles are a drug delivery platform, which have the ability to contain both biological and fabricated components to improve therapeutic efficiency and targeting. The novelty of these platforms holds promise for future clinical translation upon further investigation. In order for both exosome therapeutics and biomimetic nanoparticles to translate into large-scale clinical treatment, numerous factors must first be considered and improved. Standardization of different protocols, from exosome isolation to storage conditions, must be optimized to ensure batches are pure. Standardization is also important to ensure no variability in this process across studies, thus making it easier to interpret data across different disease models and treatments. Expansion of clinical trials incorporating both biomimetic nanoparticles and exosomes will require a standardization of fabrication and isolation techniques, as well as stricter regulations to ensure reproducibility across various studies and disease models. This review will summarize current research on exosome therapeutics and the application of biomimetic nanoparticles in cardiac regenerative medicine, as well as applications for exosome expansion and delivery on a large clinical scale.
Export Options
About this article
Cite this article as:
Stine J. Sydney , Popowski D. Kristen , Su Teng and Cheng Ke *, Exosome and Biomimetic Nanoparticle Therapies for Cardiac Regenerative Medicine, Current Stem Cell Research & Therapy 2020; 15 (8) . https://dx.doi.org/10.2174/1574888X15666200309143924
DOI https://dx.doi.org/10.2174/1574888X15666200309143924 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The MAPK / JNK Signalling Pathway Offers Potential Therapeutic Targets for the Prevention of Acquired Deafness
Current Drug Targets - CNS & Neurological Disorders Angiotensin Converting Enzyme 2 Activator (DIZE) Modulates Metabolic Profiles in Mice, Decreasing Lipogenesis
Protein & Peptide Letters Multi-Modality Cardiac Imaging in Interventional Cardiology
Current Medical Imaging The Effect of Antihypertensive Drugs on Central Blood Pressure Beyond Peripheral Blood Pressure. Part II: Evidence for Specific Class-Effects of Antihypertensive Drugs on Pressure Amplification
Current Pharmaceutical Design Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews C. elegans Genetic Networks Predict Roles for O-GlcNAc Cycling in Key Signaling Pathways
Current Signal Transduction Therapy Refractory Angina Pectoris: Lessons from the Past and Current Perspectives
Current Pharmaceutical Design Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Current Neurovascular Research Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk
Current Vascular Pharmacology Dietary Antioxidants and Oxidative Stress from a Human and Plant Perspective: A Review
Current Nutrition & Food Science Life Threatening and Fatal Contrast Media Reactions: Pathomechanisms, Diagnosis, Prevention and Drug Management
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cardioprotective Effects of Natural Products <i>via</i> the Nrf2 Signaling Pathway
Current Vascular Pharmacology Severe Acute Respiratory Syndrome (SARS): A Brief Review With Exploration of the Outcomes, Prognostic Factors and Sequelae
Current Respiratory Medicine Reviews Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry 1, 4-Dihydropyridines: A Class of Pharmacologically Important Molecules
Mini-Reviews in Medicinal Chemistry Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design